News 28.02.2020 Zurich, Switzerland – February 27, 2020 – Neurimmune AG, the discoverer of aducanumab and cinpanemab, announced today enrollment of the first patient in a Phase 1 clinical trial to evaluate NI006 in transthyretin amyloid cardiomyopathy (ATTR cardiomyopathy). NI006 is a human antibody directed against transthyretin amyloid (TTR amyloid) consisting of misfolded...
Internal events 28.02.2020
News 26.02.2020 Zurich-Schlieren, Switzerland, February 26, 2020. Proteomedix, the Swiss cancer diagnostics company, announced today that Proclarix, its blood-based test for prostate cancer diagnosis, has now been made commercially available in Europe. Proclarix combines proprietary biomarkers and a risk score that accurately identifies an individual patient’s risk for clinically significant prostate cancer. The...
Internal events
Event date: 19.03.2020
Biologics Networking & Knowledge Exchange powered by Lonza
19 March, 2020 at 15:30 followed by an apero
Bio-Technopark Auditorium, Wagistrasse 25, 8952 Schlieren, Switzerland
How do you ensure that your first milestone into the clinic is not your last? Join us to get a head start to IND without jeopardising your drug's future.
Advancing an...
News 20.02.2020 Zurich-Schlieren, Switzerland, February 20, 2020. Molecular Partners AG (SIX: MOLN), a clinicalstage biotech company that is developing a new class of drugs known as DARPin® therapies, today announced the nomination of three new board members, proposed for election at the 2020 Annual General Meeting on April 29, 2020. Nominees are as follows: • Sandip...